-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VJi1zQWIlkT/+n0GmkyINVRAGuSvTfMJTj+A3bJcL73qSZYHkSvaWQyNEGvt88vc yU2mWmlPI90L6vnDnwS9jg== 0001031599-05-000011.txt : 20050929 0001031599-05-000011.hdr.sgml : 20050929 20050929150728 ACCESSION NUMBER: 0001031599-05-000011 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050929 DATE AS OF CHANGE: 20050929 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOJECT MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000810084 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 931099680 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-40150 FILM NUMBER: 051111109 BUSINESS ADDRESS: STREET 1: 211 SOMERVILLE ROAD STREET 2: ROUTE 202 NORTH CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: 9084702800 MAIL ADDRESS: STREET 1: 211 SOMERVILLE ROAD STREET 2: ROUTE 202 NORTH CITY: BEDMINSTER STATE: NJ ZIP: 07921 FORMER COMPANY: FORMER CONFORMED NAME: BIOJECT MEDICAL SYSTEMS LTD DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FLYNN EDWARD L CENTRAL INDEX KEY: 0001031599 FILING VALUES: FORM TYPE: SC 13D BUSINESS ADDRESS: STREET 1: 75 11 MYRTLE AVE CITY: GLENDALE STATE: NY ZIP: 11385 BUSINESS PHONE: 7183865800 MAIL ADDRESS: STREET 1: 211 SOMERVILLE ROAD RTE 202N CITY: BEDMINISTER STATE: NJ ZIP: 07921 SC 13D 1 flynnschedule13d.txt EDWARD L. FLYNN SCHEDULE 13D Portlnd2-4531750.1 0031038-00001 OMB APPROVAL UNITED STATES OMB Number:3235-0145 SECURITIES AND EXCHANGE COMMISSION Expires:December 31, 2005 Washington, D.C. 20549 Estimated average burden hours per response 11 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Bioject Medical Technologies, Inc. (Name of Issuer) Common Stock, No Par Value Per Share (Title of Class of Securities) 09059T-206 (CUSIP Number) Edward L. Flynn Owner and Chief Executive Officer Flynn Meyer Company 75-11 Myrtle Avenue Glendale, NY 11385 (718) 386-5800 Copy to: Todd A. Bauman, Esq. Steven H. Hull, Esq. Stoel Rives LLP 900 S.W. Fifth Avenue, Suite 2600 Portland, OR 97204 (503) 224-3380 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 5, 2005 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d- 1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 09059T-206 1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Edward L. Flynn 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a) (b) 3. SEC Use Only 4. Source of Funds (See Instructions): PF 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization: USA Number of 7. Sole Voting Power 694,086 (1) Shares Beneficia lly Owned by Each Reporting Person Wi th 8. Shared Voting Power 61,047 9. Sole Dispositive Power 694,086 10.Shared Dispositive Power 61,047 11. Aggregate Amount Beneficially Owned by Each Reporting Person 755,133 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11)5.45% (2) 14. Type of Reporting Person (See Instructions) IN Notes: 1. See Items 3 and 4 of this Schedule 13D. 2.Based on the number of shares of Bioject Medical Technologies, Inc. common stock represented by Bioject Medical Technologies, Inc. to Mr. Flynn as outstanding as of September 15, 2005, the Shares represent approximately 5.45% of the outstanding shares of Bioject Medical Technologies, Inc. common stock. Item 1. Security and Issuer This Schedule 13D relates to the common stock of Bioject Medical Technologies, Inc., a Oregon corporation ("Bioject"). The principal executive offices of Bioject are located at Bedminster Professional Center, 211 Somerville Road (Route 202 North), Bedminster, NJ 07921. Item 2. Identity and Background (a)-(c), (f) The name of the person filing this Schedule 13D is Edward L. Flynn. Mr. Flynn currently serves as the owner and Chief Executive Officer of Flynn Meyer Co., whose address is 75-11 Myrtle Avenue, Glendale, NY 11385. Flynn Meyer Co. owns and operates a number of McDonald's Restaurant franchises. Mr. Flynn is a citizen of the United States. (d) Mr. Flynn is not required to disclose legal proceedings pursuant to Item 2(d). (e) Mr. Flynn is not required to disclose legal proceedings pursuant to Item 2(e). Item 3. Source and Amount of Funds or Other Consideration On September 6, 2005, Mr. Flynn purchased 8,540 shares of Bioject Common Stock on the open market for $12,767.30. On August 24, 2005, Mr. Flynn purchased 12,500 shares of Bioject Common Stock on the open market for $20,162.50. On August 18, 2005, Mr. Flynn purchased 8,000 shares of Bioject Common Stock on the open market for $13,260. On August 16, 2005, Mr. Flynn purchased 17,000 shares of Bioject Common Stock on the open market for $29,920. On August 8, 2005, Mr. Flynn purchased 15,000 shares of Bioject Common Stock on the open market for $26,878.50. On August 5, 2005, Mr. Flynn purchased 8,200 shares of Bioject Common Stock on the open market for $15,006.00. All of the funds used were personal funds. Item 4. Purpose of Transaction Mr. Flynn acquired shares of Common Stock for investment purposes. Mr. Flynn has no existing plans or proposals that include or may result in: (a) the acquisition of additional securities of the Company or the disposition of securities of the Company, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, (c) a sale or transfer of a material amount of assets of the Company or any of its subsidiaries, (d) any change in the present board of directors or management of the Company, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board, (e) a material change in the present capitalization or dividend policy of the Company, (f) any other material changes in the Company's business or corporate structure, (g) changes in the Company's charter, bylaws or instruments corresponding thereto, or other actions that may impede the acquisition of control of the Company by any person, (h) causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system, (i) causing a class of equity securities of the Company to become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (j) any action similar to the foregoing actions. Item 5. Interest in Securities of the Issuer (a) Mr. Flynn beneficially owns 755,133 shares of Bioject common stock, which represents 5.45% of the outstanding common stock of Bioject. (b) Mr. Flynn has sole voting and disposition authority for 694,086 shares. Mr. Flynn shares voting and disposition authority over 61,047 shares with Leona Flynn. Ms. Flynn serves as a partner of Flynn Meyer Co. Flynn Meyer Co. owns and operates a number of McDonald's Restaurant franchises. Ms. Flynn's business address is 75-11 Myrtle Avenue, Glendale, NY 11385. Ms. Flynn is a citizen of the United States. Ms. Flynn is not required to disclose legal proceedings pursuant to Items 2(d) or 2(e). (c) All of the following transactions were executed on the open market within the last 60 days. Quantit Description of Security Transact Trade y ion Date Value 800 Bioject Med Tech Inc Common 6/24/200 936.00 Stock 5 600 Bioject Med Tech Inc Common 6/24/200 708.00 Stock 5 200 Bioject Med Tech Inc Common 6/24/200 240.00 Stock 5 6,037 Bioject Med Tech Inc Common 6/27/200 7,365.14 Stock 5 1,300 Bioject Med Tech Inc Common 7/1/2005 1,508.00 Stock 9,600 Bioject Med Tech Inc Common 7/27/200 12,864.0 Stock 5 0 400 Bioject Med Tech Inc Common 7/27/200 532.00 Stock 5 4,700 Bioject Med Tech Inc Common 8/1/2005 7,520.00 Stock 4,400 Bioject Med Tech Inc Common 8/1/2005 6,732.00 Stock 100 Bioject Med Tech Inc Common 8/1/2005 159.00 Stock 5,200 Bioject Med Tech Inc Common 8/1/2005 8,372.00 Stock 10,000 Bioject Med Tech Inc Common 8/2/2005 15,500.0 Stock 0 18,000 Bioject Med Tech Inc Common 8/4/2005 29,700.0 Stock 0 10,000 Bioject Med Tech Inc Common 8/4/2005 16,200.0 Stock 0 8,200 Bioject Med Tech Inc Common 8/5/2005 15,006.0 Stock 0 15,000 Bioject Med Tech Inc Common 8/8/2005 26,878.2 Stock 0 17,000 Bioject Med Tech Inc Common 8/16/200 29,920.0 Stock 5 0 8,000 Bioject Med Tech Inc Common 8/18/200 13,260.0 Stock 5 0 12,500 Bioject Med Tech Inc Common 8/24/200 20,162.5 Stock 5 0 8,540 Bioject Med Tech Inc Common 9/6/2005 12,767.3 Stock 0 (d) Not applicable. (e) Not applicable. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer There are no contracts, arrangements, understandings or relationships between Mr. Flynn and any other person with respect to any securities of Bioject, including, but not limited to, transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Item 7. Material to Be Filed as Exhibits None. (Signature page follows.) SIGNATURES After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: ___________, 2005 By: _________________________________ Name: Edward L. Flynn Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (See 18 U.S.C. 1001) -----END PRIVACY-ENHANCED MESSAGE-----